Associated Papers
From sample to clinical insight: a review of exome sequencing in disease diagnostics.
Manjunath GK et al.
Methods (san Diego, Calif.), 2026
Comparative genomic and clinicopathological analysis uncovers contrasting molecular profiles of canine and human thyroid carcinomas.
Das S et al.
Communications Biology, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies.
Veas Rodriguez J et al.
Journal for Immunotherapy of Cancer, 2025
Molecular Characterization and Subtyping of Breast Cancer Cell Lines Provide Novel Insights into Cancer Relevant Genes.
Pommerenke C et al.
Cells, 2024
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J et al.
Frontiers in Oncology, 2023
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Soria-Bretones I et al.
Science Advances, 2022
Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.
Szpechcinski A et al.
Cancers, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53.
Butz H et al.
Frontiers in Oncology, 2022
Aberrant Signaling Pathways in Sinonasal Intestinal-Type Adenocarcinoma.
Riobello C et al.
Cancers, 2021
Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
Lim Y et al.
Scientific Reports, 2021
Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J et al.
International Journal of Molecular Sciences, 2021
Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.
Braunstein EM et al.
Cancers, 2021
Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility.
Bao R et al.
Cancer Prevention Research (philadelphia, Pa.), 2021
Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer.
Niwinska A et al.
Diagnostics (basel, Switzerland), 2020
Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies.
Prieto-Potin I et al.
Peerj, 2020
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D et al.
Journal of the National Cancer Institute, 2019
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S et al.
Cancer, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.
Kemper K et al.
Cell Reports, 2016
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z et al.
Journal of Cellular and Molecular Medicine, 2015
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
Stanton SE et al.
Bmc Cancer, 2015
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Boulbes DR et al.
Molecular Oncology, 2015
A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.
Jupe ER et al.
Bba Clinical, 2014
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
Bodian DL et al.
Plos One, 2014
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.
Rodrigues P et al.
Molecular and Cellular Biochemistry, 2013
Heritable variation of ERBB2 and breast cancer risk.
Breyer JP et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2009
Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach.
Rajasekaran R et al.
Comptes Rendus Biologies, 2008
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.
Frank B et al.
Journal of the National Cancer Institute, 2008
A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
Lee SC et al.
Clinical Biochemistry, 2008
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
Beauclair S et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2007
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.
Li E et al.
Biochemistry, 2006
Reply: a bias in genotyping of the ERBB2 (HER2) Ile655Val variant.
Benusiglio PR et al.
Carcinogenesis, 2005
A bias in genotyping the ERBB2 (HER2) Ile655Val variant.
Frank B et al.
Carcinogenesis, 2005
Familial cancer and ARLTS1.
De Brakeleer S et al.
The New England Journal of Medicine, 2005
A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.
Frank B et al.
Carcinogenesis, 2005